We are delighted to announce that our "ichroma™ Tumor triple-M" has acquired the export approval from the Ministry of Food and Drug Safety. The newly released product can measure three types of tumor markers (PSA, AFP, and CEA) simultaneously, which are used as auxiliary roles in early diagnosis of universal cancer diseases such as prostate cancer, liver cancer, and colon cancer.
Prostate specific antigen (PSA) is useful as a biomarker for evaluating the therapeutic effectiveness of prostate cancer and recurrence. In addition to prostate cancer, it can be used as a positive indicator for prostate hyperplasia and acute prostatitis. Alpha-Fetoprotein (AFP) is a biomarker used for early diagnosis of liver cancer or prenatal screening. Carcinoembryonic Antigen (CEA) is a pan-species marker that widely appears in tumors of various organs such as colorectal cancer, gastric cancer, pancreatic cancer, lung cancer, and breast cancer, and is mainly useful for observing the process of colon cancer treatment.
Tumor marker tests are basically used as a means of screening and tracking cancer, prognosis, and prediction before and after surgery, and their utilization is rapidly expanding as the importance of early detection and treatment of cancer is emphasized. According to the population aging of major advanced countries, as social costs related to cancer treatment are increasing rapidly, the early diagnosis market that can prevent it in advance is also growing rapidly.
A company official said, "The early diagnosis market for cancer diseases is mainly dominated in major advanced markets, but it is expected to grow rapidly in Asian and Latin American markets as the high-cost structure of tumor marker tests improves expeditiously. The newly released product from Boditech Med can simultaneously measure major tumor markers in the field within 15 minutes using whole blood. This has the advantage of drastically reducing cost and inspection time compared to competing products. It is expected to contribute greatly to stable overseas sales expansion after COVID-19".